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ABSTRACT 55 
Ocular stem cell transplantation derived from either autologous or allogeneic donor 56 
corneoscleral junction is a functional cell therapy to manage extensive and/or severe 57 
limbal stem cell deficiencies that lead to corneal epithelial failure. Mesenchymal stem 58 
cells have been properly tested in animal models of this ophthalmic pathology, but 59 
never in human eyes despite their potential advantages. We conducted a 6- to 12-60 
month proof-of-concept, randomized, double-masked pilot trial to test whether 61 
allogeneic bone marrow-derived mesenchymal stem cell transplantation (MSCT, 62 
n=17) was as safe and as equally efficient as allogeneic cultivated limbal epithelial 63 
transplantation (CLET, n=11) to improve corneal epithelial damage due to limbal 64 
stem cell deficiency. Primary endpoints demanded combination of symptoms, signs, 65 
and the objective improvement of the epithelial phenotype in central cornea by in-vivo 66 
confocal microscopy. This proof-of-concept trial showed that MSCT was as safe and 67 
efficacious as CLET. Global success at 6-12 months was 72.7%-77.8% for CLET 68 
cases and 76.5%-85.7% for MSCT cases (not significant differences). Central 69 
corneal epithelial phenotype improved in 71.4% and 66.7% of MSCT and CLET 70 
cases, respectively at 12 months (p=1.000). There were no adverse events related to 71 
cell products. This trial suggests first evidence that MSCT facilitated improvement of 72 
a diseased corneal epithelium due to lack of its stem cells as efficiently as CLET. 73 
Consequently, not only CLET but also MSCT deserves more preclinical 74 
investigational resources before the favorable results of this proof-of-concept trial 75 
could be transformed into the larger numbers of the multicenter trials that would 76 
provide stronger evidence. (ClinicalTrials.gov number, NCT01562002.) 77 
 78 
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INTRODUCTION 84 
Corneal epithelial failure due to extensive or severe limbal stem cell deficiency 85 
(LSCD) is an end-stage pathology resulting from multiple diseases that destroy the 86 
corneal epithelium stem cell niche, located at the sclerocorneal limbus. LSCD results 87 
in recurrent corneal epithelial ulceration, neovascularization, and opacification 88 
because of the inability of the limbal niche to renew the corneal epithelium.1–3 89 
Corneal transplantation is not a viable primary solution as the donor tissue cannot 90 
replace the damaged corneal epithelial stem cells.4 The first attempts to replace 91 
native limbal epithelial cells were to transplant whole limbal tissue from donor eyes.5 92 
More recently, single limbal epithelial transplantation places small pieces of limbal 93 
tissue (not isolated cells) from the healthy fellow eye.6 In 1997, stem cell-based 94 
therapies based on cultivated limbal epithelial cells commenced a significant 95 
breakthrough in regenerative medicine7 and are currently an established therapy, 96 
both from autologous and allogeneic sources, the latter used when there is no 97 
possibility of a healthy donor contralateral eye.2,4,8–12 Human amniotic membrane 98 
(hAM) transplantation, useful in sectoral and mild LSCD and an excellent cell carrier 99 
for stem cell growth and transplantation, has not been shown to help LSCD cases 100 
that are total and/or severe.13,14 In this study, we explored, for the first time in human 101 
eyes in which medical therapy had failed, the potential capacity of mesenchymal 102 
stem cells (MSC) to treat corneal epithelial pathology due to LSCD.15–17 MSC could 103 
have potential advantages over limbal epithelial stem cells for this purpose because 104 
they can be easily obtained from many tissue types without dependence of deceased 105 
donors.18 Additionally, they can be cultured in vitro to clinical scales in a short period 106 
of time, overcoming the dependence on and the limitations of limbal epithelial cells, 107 
which are difficult to obtain, isolate, and culture and have limited availability.19,20 108 
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Moreover, cryopreserved MSC can be transplanted without loss of potency,21 109 
whereas cryopreserved limbal epithelial stem cells have not been transplanted in 110 
humans yet.22,23 Finally, allogeneic MSC can be transplanted without the need of 111 
host immunosuppression,20,24,25 while allogeneic transplantation of limbal epithelial 112 
stem cells requires one year of systemic immunosuppression to avoid immune 113 
rejection.9,11  114 
We report herein a proof-of-concept clinical trial aimed to evaluate the initial safety 115 
and clinical efficacy of MSC versus the established therapy with limbal epithelial cells 116 
for corneal epithelial pathology due to LSCD. An initial clinical success would warrant 117 
the economic expenditure necessary to carry out a more thorough investigation of 118 
the mechanism of action of not only limbal stem cells but also MSC before 119 
proceeding with larger clinical trials.  120 
 121 
MATERIAL AND METHODS  122 
Study design and patients 123 
This was a Phase I-II randomized, controlled, double-masked, unicenter clinical trial 124 
based on the hypothesis that allogeneic bone marrow-derived mesenchymal stem 125 
cell transplantation (MSCT) is as safe and effective as allogeneic cultivated limbal 126 
epithelial transplantation (CLET) to treat patients with total and/or severe LSCD. 127 
It was designed as a proof-of-concept clinical trial to include only the minimum 128 
required number of transplants necessary to prove the hypothesis. 129 
The protocol (EudraCT 2010-023535-42) was approved by the local Ethics 130 
Committee of our institution and the Spanish Agency of Medicines and Sanitary 131 
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Products (AEMPS, www.aemps.gob.es). The Clinical Trials.gov Identifier is 132 
NCT01562002. 133 
All procedures were conducted in accordance with the principles of the Declaration of 134 
Helsinki, good manufacturing and clinical practice guidelines, and the European 135 
Union Tissues and Cells Directive. All patients gave written informed consent. The 136 
trial was sponsored by our institution, Advanced Therapies Unit, University of 137 
Valladolid, Spain, under the guidance of the Advanced Therapies National Program 138 
(Ministry of Heath, Government of Spain).  139 
We enrolled adult patients with bilateral and severe disease, as it is ethically 140 
indicated in an exploratory proof-of-concept clinical trial. The following 141 
inclusion/exclusion criteria were met: (1) diagnosis of target disease characterized by 142 
(a) corneal epithelial failure because of LSCD graded as total and/or severe, 143 
meaning that at least three quadrants of the limbus were damaged (as visualized by 144 
slit-lamp) and/or that the central cornea was involved9; (b) invariably accompanied by 145 
blindness or low vision due to opacified central cornea; and (c) in which all available 146 
medical therapies (i.e., topical medications and hAM transplantations mainly in acute 147 
phases of chemical injuries) had failed (Tables 1 and 2 for detailed previous 148 
treatment in each patient); (2) no ocular surgeries in the previous 6 months other 149 
than another cell transplant within this trial; (3) the affected eye had to have 150 
undergone medical therapies to quiet and reverse as much as possible any treatable 151 
limbal dysfunction; and (4) no contraindications for immunosuppressive therapies. 152 
As the final outcome of cell transplantation strongly depends on the etiology of limbal 153 
damage, the following three etiological categories were considered11 at the initial 154 
visit: Chemical injuries; immune-based inflammatory diseases (e.g. Stevens-Johnson 155 
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syndrome, mucous membrane pemphygoid, atopic keratoconjunctivitis); and other 156 
less inflammatory conditions (e.g., sequelae from multiple surgeries, chronic 157 
sequelae from infectious keratitis, congenital aniridia). The allocation to the two 158 
treatment groups (see below) was balanced according to these etiologies. 159 
 160 
Randomization and masking 161 
After screening for inclusion/exclusion criteria and balancing the allocation of the 162 
three prognostic etiologic categories, all scheduled transplants were randomly 163 
allocated in a 1:1 ratio to CLET or MSCT. Randomization was balanced by the use of 164 
permuted blocks of varying block size with a maximum size of 6. The randomization 165 
schedule was computer-generated (R Statistical Software). When both eyes of a 166 
patient were to receive transplants, the use of CLET or MSCT was randomly 167 
assigned so that both eyes did not necessarily receive the same type of transplant. 168 
Some eyes, due to the failure of the transplant, received more than one 169 
transplantation. For each repeated surgery, the assignment of CLET or MSCT was 170 
random. Thus the new transplants, CLET or MSCT, were not necessarily the same 171 
as the preceding one that failed. 172 
The Cell Processing Unit staff was aware of group assignment to prepare either cell 173 
product. The only difference in the final package that arrived at the Medical Institution 174 
the day of surgery was the type of cell cultivated, which was impossible to discern by 175 
the naked human eye. Everything else, including the packaging, was identical and 176 
followed the good manufacturing procedures. The products were identified by the 177 
randomization number, and only the Statistical Unit and the Cell Processing Unit 178 
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knew the identity of each product. All attending sanitary personnel and the patients 179 
themselves were completely masked as to the type of cells being transplanted.  180 
 181 
Procedures 182 
Cells destined for CLET or MSCT (investigational products 09-137 and 10-134, 183 
respectively) were cultured on top of hAM at the University of Valladolid Cell 184 
Processing Unit, operating under good manufacturing practices and licensed and 185 
accredited by the AEMPS. Donor hAM and cadaveric limbal rings (≤60 years of age) 186 
came from a registered and accredited tissue bank (Blood-Tissue Community Center, 187 
Oviedo, Spain). Bone marrow from iliac crest was collected from allogeneic donors 188 
≤60 years of age who gave written consent and were under other approved trials.26–28 189 
De-epithelialized hAM (size 2.5x2.5 cm) were prepared using our published standard 190 
protocol11 and served as the substratum for both cell types. For CLET, two 2x2 mm 191 
pieces of allogeneic limbal rings were processed and cultured, as described.11 For 192 
MSCT, allogeneic MSC were obtained and characterized as reported,26–28 analyzing 193 
CD90, CD73, CD166, and CD105 as positive markers and CD14, CD34, CD45, and 194 
HAD-DR as negative markers in accordance with the International Society for 195 
Cellular Therapy (ISCT) position statement.29 The cell products were harvested when 196 
the cultured cells were ~90% confluent (~250,000 cells). For the limbal epithelial 197 
cells, this took 3-4 weeks, and for the MSC it took 3-5 days. The quality criteria for 198 
the cell products were (1) sterility, (2) hAM integrity, (3) adherence of the hAM to the 199 
plate, (4) 80-90% of cell confluence (monolayer) observed under inverted phase 200 
contrast microscopy, and (5) cell morphology (polygonal shape for CLET and spindle 201 
shape for MSCT) observed under inverted phase contrast microscopy. After 202 
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determining that the cultures were negative for aerobes, anaerobes, fungi, and 203 
mycobacteria, they were delivered within 4 h of surgery. Some of the cultures that 204 
were assigned to patients who cancelled their surgeries (see below) were allowed to 205 
finish growing and later processed for immunostaining to test for limbal, 206 
mesenchymal, and differentiated corneal epithelial cell markers, as previously 207 
published30,31 (see Supplementary Appendix for more details). To prevent any 208 
possible immune allograft rejection, patients receiving CLET underwent a mild 209 
immunosuppressive therapy.11 While patients receiving MSCT would not normally 210 
need such therapy due to the absence of immune rejection by allogenic MSC,15–211 
17,24,25 oral immunosuppression was instituted to eliminate immune suppression as a 212 
variable and to maintain the double masked nature of the study; otherwise, the trial 213 
could not have been masked. Thus, all patients were started at the initial visit on 1.5-214 
2.0 g/day of mycophenolate mofetil; 3-5 mg/kg/day of cyclosporine A, or 1-2 215 
mg/kg/day of azathioprine were also permitted if, for any reason, mycophenolate 216 
mofetil was not available or the patient was already using one of the other two 217 
immunomodulating agents. This treatment was maintained for 12 months after 218 
transplantation and discontinued in the next 3 months. We closely monitored 219 
potential side effects clinically and by blood/urine work-ups every 1-2 months. No 220 
other systemic medications were added. 221 
Surgery took place 3-4 weeks after the initial visit, and all were performed using the 222 
identical technique by the same experienced surgeon.11 Briefly, after preparing the 223 
recipient corneal-limbal bed (i.e. scraping off the corneal-limbal pannus), hAM with 224 
cells for either CLET or MSCT were placed with the membrane facing up and the 225 
cells facing down, to facilitate their fast as possible access to the damaged corneal 226 
and limbal bed. In this way, the cells were in direct physical and functional contact 227 
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with the tissues to be repaired and protected from the external environment by the 228 
hAM. The transplant was sutured to the bared sclera and covered with a bandage 229 
contact lens for 4 weeks.  230 
Twenty-four hours after surgery, each patient was evaluated and topical treatment 231 
with the fixed combination of 1% prednisolone acetate and 0.3% tobramycin 232 
(Tobradex®, Alcon Laboratories, FT. Worth, TX, USA) was prescribed 4 times per 233 
day until the hAM dissolved. The stitches and the contact lens were also removed 234 
between 4 and 6 weeks. Then, 1 mg/ml dexamethasone (Maxidex®, Alcon 235 
Laboratories) was instilled 4 times a day and slowly tapered in the next 3 months. 236 
Anti-glaucoma medications were the only other topical medication allowed (other 237 
than lubricants) and only in those patients who were previously using them, as they 238 
had already been diagnosed with glaucoma. The patients were evaluated 24 h, 1 239 
week, and 4 weeks after surgery. Evaluations were then performed every month for 240 
the first 6 months, and every two months until the first year. All personnel related to 241 
patient care, and the patients themselves, were masked as to the type of cells 242 
transplanted.  243 
 244 
Outcomes 245 
Evaluation endpoints were collected at the initial baseline visit and at 6 months and 246 
12 months. Three self-administered questionnaires evaluated symptoms and quality 247 
of life: the Single Item Dry Eye Questionnaire (SIDEQ), the Ocular Surface Disease 248 
Index (OSDI), and the National Eye Institute 25-item Visual Function Questionnaire 249 
(NEI-VFQ25).32,33 The following clinical signs were evaluated by slit-lamp 250 
biomicroscopy: conjunctival redness, central corneal epithelial opacity, corneal 251 
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epithelial integrity manifesting as superficial keratitis and persistent epithelial defects, 252 
and corneal superficial neovascularization (area/length) (Table 3). 253 
Visual acuity was determined as mandatory in clinical trials, although improved acuity 254 
is never the aim of these kind of trials. Procedures such as stem cell transplantation 255 
are intended to promote recovery of the corneal epithelium. Even with successful 256 
repair of the corneal epithelium, visual deficiency may continue due to deeper 257 
corneal damage (e.g., full thickness corneal destruction in severe chemical burns) or 258 
involvement of other parts of the eye (e.g., pre-existing cataract or various anomalies 259 
such as glaucoma, retinal pathology, etc.). In fact, we determined the presence of 260 
these factors before surgery to inform patients of what to expect in terms of visual 261 
recovery (Table 3). 262 
We used in vivo confocal microscopy (IVCM) (Heidelberg Retinal Tomograph HRT-3 263 
and Rostock Cornea Module, Heidelberg Engineering GmbH, Heidelberg, Germany) 264 
to image the basal epithelium phenotype in the central cornea, as described by 265 
us11,34 and others.35–37 The confocal images are used to determine the presence of 266 
the normal homogenous corneal epithelial cell phenotype as well as conjunctival-like 267 
or mixed epithelial cell phenotypes typically present in the damaged central cornea. 268 
This provided an objective assessment of the presence of LSCD in central cornea 269 
and of the efficacy of restoration therapies (Table 3). See Supplementary Appendix 270 
for details on all end-points. 271 
The primary outcomes were as follows: (1) improvement in any of the three 272 
questionnaires; (2) improvement by at least one step in at least two of the three 273 
following clinical parameters: conjunctival redness, central corneal epithelial opacity, 274 
or superficial punctate keratitis; (3) complete absence of persistent epithelial defects; 275 
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and (4) presence of a more corneal epithelial-like phenotype in the central cornea. 276 
The change in epithelial phenotype could be either a change from a conjunctival-like 277 
epithelium to either a corneal-like or a mixed epithelial phenotype or from a mixed 278 
epithelial phenotype to a corneal-like epithelium phenotype.11 Secondary outcomes 279 
included (1) amelioration of at least a one-step in superficial corneal peripheral 280 
neovessels (area/length) and (2) vision improvement of two lines or more in those 281 
cases that had the potential of vision gain with this cell transplantation alone and no 282 
additional surgeries (Table 3, column: Visual Prognosis and Potential for Visual 283 
Recovery, Grade 1 patients).  284 
The outcome was considered successful when either a complete or a partial success 285 
was accomplished. A complete success meant that all four primary outcomes were 286 
achieved, and a partial success meant that at least two of the four primary outcomes 287 
or one primary and one secondary outcome were achieved. Failure meant that only 288 
one or none of the primary outcomes was met.11 289 
 290 
Statistical analysis 291 
Statistical analyses were performed by a PhD licensed statistician, who estimated 292 
that a sample of 10 transplants per group would give 80% statistical power to detect 293 
the non-inferiority of the experimental group. The calculations assumed a success 294 
rate of 80% in each group and a non-inferiority margin of 25% at an alpha level of 295 
0.05. Consequently it was considered that a minimum of 10 transplants per group 296 
was sufficient for the exploratory nature of this proof-of-concept trial. 297 
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Quantitative characteristics were expressed as means ± standard deviations (SD), 298 
and qualitative variables were described as percentages. The median and 299 
interquartile range (IQR) were used to summarize distributions of ordinal variables. 300 
Normality assumptions were checked by the Shapiro-Wilk test. Differences between 301 
the means of two independent groups were tested by Student’s t-test or the non-302 
parametric alternative, Mann-Whitney U test, if the normality assumption was not 303 
valid. Levene’s test was used to check homogeneity of variance. Relationships 304 
between two qualitative variables were evaluated by chi-square test or Fisher’s exact 305 
test with small expected cell counts. Analysis of variance (ANOVA) with repeated 306 
measures on one factor was utilized to test for mean differences over time. The 307 
sphericity assumption was checked by Mauchly’s test and, in case of violation of 308 
sphericity, the Greenhouse-Geisser correction was used. If there were differences in 309 
the repeated ANOVA measures, Bonferroni post hoc testing was used to determine 310 
where differences lay in a pairwise analysis. When data had marked deviations from 311 
the normality assumption Friedman’s test was used, followed by the post hoc 312 
analysis based on Wilcoxon-Nemenyi-McDonald-Thompson test. Kaplan-Meier 313 
survival analysis was applied to estimate transplant survival. The log-rank test was 314 
used to compare the survival curves of each transplant type. The R Statistical 315 
Software version 3.1.3 was used (Foundation for Statistical Computing, Vienna, 316 
Austria). 317 
 318 
RESULTS 319 
Clinical trial sample  320 
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We initially recruited 27 Caucasian patients (36 eyes, 42 potential transplants) (Fig 321 
1). Five patients (10 eyes) cancelled surgery due to different personal/logistical 322 
reasons. Therefore, the final number of transplant surgeries was 37 (26 eyes, 22 323 
patients). Among them, 16 cases were randomized to CLET and 21 to MSCT. Nine 324 
cases (24.3% of the total 37; 95% confidence interval [CI], 12.4 to 41.6), 5 CLET and 325 
4 MSCT, lost their transplants within the first week due to loss of the bandage contact 326 
lens. Based on our preclinical data (unpublished), we considered that stem cells may 327 
have not completely reached their tissue target in less than 7 days, thus these 328 
transplants were excluded. 329 
We consequently included in this trial 28 transplant surgeries from 23 eyes (20 330 
patients), 11 cases were randomized to CLET and 17 to MSCT that were fully 331 
assessable at the minimum established period of 6 months (Fig 1). Of those, 23 332 
reached 12 month follow-up and only 5 transplants did not: one (MSCT-2) was 333 
withdrawn due to a violent relapse of concomitant atopic dermatitis and its ocular 334 
component, atopic keratoconjunctivitis, that ruined his transplant and also worsened 335 
considerably his fellow non-transplanted eye. The other 4 cases were successfully 336 
re-grafted for the benefit of the patient (2 failed MSCTs; 1 failed CLET, 1 partially 337 
successful CLET). See Tables 1 and 2 for more details. 338 
Table 4 shows the summary characteristics of the 28 fully assessable cell 339 
transplants; the detailed characteristics at baseline, 6 months, and 12 month of each 340 
case are shown in Tables 1 and 2. 341 
Patients with assessable transplants had a mean age of 49.3±10.8 years (range, 28-342 
77 years). Females comprised 42.9% (95% CI, 25 to 62.6) of the transplant 343 
recipients and males 57.1% (95% CI, 37.4 to 75) (p=0.253). The assignment of 344 
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patients to the CLET or MSCT groups was statistically independent of age or gender 345 
(Table 4). Time from LSCD to cell transplant was not significantly different between 346 
CLET and MSCT (Table 4). 347 
The etiology groups leading to the target disease and the severity and extension of 348 
the disease were equally distributed between CLET and MSCT patients (Table 4). 349 
Consequently the different nature and severity of the background disease had no 350 
influence in the results. As this was an initial pilot trial, we decided not to restrict 351 
access regardless of the etiology. 352 
Although we intended to transplant only one eye in this proof-of-concept trial, 4 cases 353 
had transplants in both eyes to attend patient demands, because both eyes were 354 
highly symptomatic and had not responded to medical therapy or to previous hAM 355 
transplantations (see inclusion criteria).  356 
There were no intra- or post-operative complications. No episodes of immune 357 
rejection were recorded. Oral immunosuppression was used in all 28 transplant 358 
cases. Mycophenolate mofetil was prescribed in 12 cases (3 CLET, 9 MSCT), 359 
cyclosporine A in 6 cases (2 CLET, 4 MSCT); and azathioprine in 7 cases (4 CLET, 3 360 
MSCT). Three patients had two immunosuppressants concomitantly due to their 361 
systemic disease. The drugs were well tolerated in all cases, and no discontinuations 362 
were necessary. Mycophenolate mofetil had to be lowered from 2 g/day to 1.5 or 1 363 
g/day in 3 cases due to asthenia. Cyclosporine A was also lowered from 5 to 3 364 
mg/kg/day in two cases due to mild elevation in blood pressure. 365 
There were 3 serious adverse events and 21 non-serious adverse events, including 366 
10 that were mild and 11 that were moderate to severe (Table 5). All were unrelated 367 
to the type of cell transplantation. Most were due to activation or recurrence of 368 
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baseline disease, and some were attributable to the concomitant 369 
immunosuppression.  370 
 371 
Final outcome and survival analysis 372 
The overall success for all cell transplants after 6 months was 75% (21 of 28 cases: 373 
13 complete successes, 8 partial successes). After 12 months, the success rate was 374 
82.6% (19 of 23: 15 complete successes, 4 partial successes). Five transplants were 375 
evaluated until month 6 (4 regrafts, one withdrawal), accounting for the different 376 
percentages. Except for CLET-2 and MSCT-15 that went from partial successes at 6 377 
months to complete successes at 12 months, the final fate of all transplants was 378 
already established at 6 months. 379 
The percentage of successful cases at 6 and 12 months was slightly higher for 380 
MSCT (76.5% and 85.7% respectively) than for CLET (72.7% and 77.8% 381 
respectively), but the differences were not statistically significant (Table 4). Thus, the 382 
final results were statistically independent of the type of cell transplant. 383 
All failures were in eyes with either chemical injuries (4 of 7; 57.1%) or immune-384 
mediated inflammatory diseases (3 of 7; 42.9%). None of the five non-inflammatory 385 
disease cases failed. Among chemical burns transplants, 75% were successful. Two 386 
of the failed cases were CLET, and two were MSCT. For transplants performed in 387 
inflammatory immune-based diseases, 57.1% were successful. One CLET transplant 388 
failed and two MSCT transplants failed in the same patient. Similarly, 25% of all cell 389 
transplants were immune-mediated diseases and of those, 57.1% were successful (2 390 
MSCT in the same patient and 1 CLET failed).  391 
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For primary and secondary evaluation endpoints, there were no significant 392 
differences between the two groups except for central corneal opacity, which was 393 
slightly more improved in MSCT cases (Table 4). Within each of the two groups, one 394 
of the symptom questionnaires showed improvement. Conjunctival redness and 395 
central corneal opacity also decreased and superficial corneal integrity, both keratitis 396 
and ulceration, improved for both groups (Fig 2). 397 
Evaluation of the epithelial phenotype in the central cornea by laser IVCM was the 398 
most objective primary endpoint. Based on the established criteria, complete success 399 
required that the corneal epithelial phenotype of the transplanted eyes must have 400 
improved by at least one step towards the normal corneal epithelial phenotype. At 401 
baseline, there was no significant difference in the distribution of the conjunctival-like 402 
or the mixed epithelial phenotype in the central cornea (Fisher’s exact test, baseline 403 
p=0.226). Consequently, the outcome of each type of cell transplant could not have 404 
been influenced by a more frequent presence of a more favorable phenotype before 405 
cell therapy in any of the three etiologic groups (Table 4). The change in epithelial 406 
phenotype at the central cornea (Fig 2) was not significantly different between CLET 407 
and MSCT at 6 months (p=0.524) or at 12 months (p=0.5562). After 6 months, 50% 408 
of CLET cases (95% CI, 23.7 to 6.3) and 62.5% of MSCT cases (95% CI, 35.9 to 409 
83.7) had improved the epithelial phenotype in the central cornea. At 12 months after 410 
surgery, 66.7% of CLET (95% CI, 30.9 to 91) and 71.4% of MSCT (95% CI, 42 to 411 
90.4) had improved the epithelial phenotype in the central cornea. The differences 412 
between CLET and MSCT were not significant (p=0.6891 and p=1.000 at 6 and 12 413 
months, respectively).  414 
For CLET, a corneal epithelial phenotype was present in 20.0% (95% CI, 3.5 to 55.8) 415 
and 33.3% (95% CI, 9 to 69.1) of the transplants at 6 and 12 months, respectively 416 
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(differences were not significant). For MSCT, the corneal epithelial phenotype was 417 
present in 43.8% (7 cases, 95% CI, 20.8 to 69.5) at 6 months and 57.1% (8 cases, 418 
95% CI, 29.7-81.2) at 12 months (p=0.0469, and p=0.0234, respectively). The 419 
percentage of cases reaching a corneal-like epithelial phenotype was not significantly 420 
different between CLET and MSCT at 6 (p=0.4152) or 12 months (p=0.854). Survival 421 
curve analysis showed that the differences between CLET and MSCT survival was 422 
not significant at either 6 or 12 months (log-rank test, p = 0.817, Fig 2). See Fig 3 as 423 
example. 424 
In summary, our hypothesis of non-inferiority for MSCT versus CLET was confirmed 425 
at 6 and 12 months (p=0.0446 and p=0.0244, respectively). 426 
 427 
DISCUSSION 428 
This is the first clinical trial showing that allogeneic bone marrow-derived MSC can be 429 
safely transplanted to the human ocular surface, as far as we know. By doing that in 430 
the context of a controlled double-masked randomized trial, we demonstrated that 431 
non-epithelial stem cells are safe and as efficient (MSCT 85.7% success) as corneal 432 
epithelial stem cells derived from the limbus (CLET 77.8% success) in restoring the 433 
corneal epithelial phenotype damaged due to LSCD. Due to its proof-of-concept 434 
design, the number of transplants was small but statistically sufficient to prove our 435 
hypothesis. Additionally, through the balanced allocation of different etiologies to 436 
either group, we guaranteed no bias in this sense. Finally, as in any initial exploratory 437 
trial, only severe LSCD of diverse etiology were included. 438 
hAM was used as a substrate to culture both limbal epithelial cells and MSC in the 439 
present clinical trial. hAM itself has re-epithelizing, anti-fibrotic, anti-inflammatory, 440 
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anti-angiogenic, and anti-microbial features.38 In patients with partial and/or mild 441 
LSCD, which maintain residual stem cell function, hAM transplantation can improve 442 
their clinical situation by supporting regeneration of residual limbal stem cells.39 443 
However, cell-free hAM transplantation is insufficient for regeneration of the ocular 444 
surface in patients with severe and/or total LSCD.13,14 445 
Because this is the first study of its kind, our results cannot be compared with similar 446 
studies in humans; nevertheless, they can be compared to other CLET series, 447 
including our own in which Ramirez et al. compared the CLET success rates among 448 
previous studies and found that ours was similar to or better than the others.11 449 
At present, the only techniques accepted as established therapies to recuperate from 450 
corneal epithelial failure due to limbal niche destruction is either full tissue (limbal) 451 
transplant5,6,40 or cell-based therapy.2,4,8–12,41 While other cell therapies have been 452 
proposed and tested in animals, the only established cell therapy approved so far for 453 
humans is CLET, which is based on in vitro cultivation of limbal niche cells. At 454 
present, a cell product (Holoclar®) has just been approved by the European Agency 455 
of Medicines based on a previous large study.9 The authorization includes the 456 
performance of a post-authorization multicenter trial. The approved indication for this 457 
product is moderate to severe limbal deficiency due to chemical/thermal burns, and 458 
the cells must be autologous, thus restricting all other etiologies and all bilateral 459 
cases unless a 1-2 mm2 limbal biopsy can be safely removed from one of the eyes. 460 
For bilateral cases or other etiologies, allogeneic CLET has proved to be effective in 461 
our hands,11 confirming previous studies.8,10,41,42 462 
However, CLET has several limitations. The main one is that epithelial stem cells 463 
must be extracted from their niches where they are thought to represent less than 464 
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10% of all cells.1,3 This means that the procedure is dependent upon healthy donor 465 
eyes or cadaveric donations, which may be limited. In practice, the small limbal 466 
biopsies can be lost because of contamination and/or lack of adequate growth. 467 
Typically, it takes 3-5 weeks to cultivate a sufficient quantity for transplantation. 468 
These factors make both autologous and allogenic CLET expensive and time-469 
consuming. The natural step forward is to turn to the most commonly used adult stem 470 
cell in regenerative medicine, MSC. Currently these cells are being used in clinical 471 
trials to treat multiple diseases including osteo-articular, liver, kidney, cardiac, 472 
hematological (graft-versus-host disease), lung problems, keratoconus, and 473 
preclinically in retinal repair.43–46 There is also abundant literature on the successful 474 
use of these cells in animal models of limbal deficiency or corneal burns.17,47–53 475 
Although it remains unclear if MSC can transdifferentiate into corneal epithelial 476 
cells,51–56 strong evidence suggests that other multiple mechanisms contribute 477 
simultaneously to the therapeutic action. These cells have the capacity to migrate 478 
into injured tissues53 and exert anti-inflammatory and immunomodulatory properties. 479 
They have paracrine activity via the production of multiple trophic and growth factors 480 
that reduce tissue injury and protect tissue from further adverse effects while 481 
enhancing tissue repair. Finally, they are able to stimulate development of resident 482 
stem cells.16,17,24,25,53–60 However, all of these effects have not been demonstrated in 483 
humans yet. In the case of CLET, there are preclinical data indicating that 484 
transplanted limbal cells migrate to the damaged limbal and corneal areas and that 485 
they repopulate and regenerate them to some extent.61–63 However, in humans this 486 
has never been demonstrated, mainly due to the technical difficulty of tracking in vivo 487 
the transplanted cells. 488 
23 of 44 
Most of our failures (57.1%) were chemical injuries, confirming other authors’ reports9 489 
and our own previous results.11 The second most frequent failures (42.9%) were 490 
immune-mediated inflammatory diseases. None of the cases with non-inflammatory 491 
diseases failed. The overall effectiveness of the both CLET and MSCT was high 492 
considering that 57% of the cases were chemical burns, of which 75% were 493 
successful regardless of which transplantation protocol was used. Similarly, 25% of 494 
the cases were immune-mediated inflammatory cases, of which 57% were 495 
successful. 496 
Although within each transplant type, one of the symptom questionnaires showed 497 
improvement, our experience during this trial and the previously published one11 is 498 
that patients had a lot of difficulty in expressing in writing what they were feeling. For 499 
instance, many complained about the numerous questions they needed to answer, 500 
and at the end they were not sure what to answer. Plus it was very confusing for 501 
them to answer when they had a useful remaining eye, especially in the vision-502 
related quality of life questionnaire. 503 
This trial included only severe end-stage LSCD syndromes, as is typical for initial 504 
clinical trials. Vision improvement is usually dependent on multiple factors beyond the 505 
LSCD, and consequently this was not the goal of either transplant procedure in this 506 
trial. Although some patients proceeded with further surgical measures to improve 507 
vision after the 12-month mandatory follow-up period, these procedures were beyond 508 
the scope of this study. Nevertheless, our encouraging results indicate the possibility 509 
of restoring to health less severe limbal disease with these transplants, thus 510 
preventing further corneal damage and visual deterioration. Finally, these cell 511 
transplant procedures may ultimately improve the health of the limbal niche where 512 
stem cells and other important cells normally reside. This will result in greater 513 
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success if corneal transplantation from either cadaveric donors or by artificial corneas 514 
becomes necessary, making the cell transplantation procedures complementary to 515 
the tissue transplantation procedures. 516 
 517 
CONCLUSIONS 518 
In summary, we have shown in this proof-of-concept clinical trial that MSC used in 519 
MSCT can safely and effectively help treating corneal pathology due to LSCD. 520 
Further progress in treating severe and blinding pathology due to LSCD will depend 521 
on more research that explores the mechanism by which the transplanted stem cells 522 
improve the corneal surface cell phenotype. One of the next steps is to organize 523 
multicenter clinical trials of both MSCT and CLET. However before that can occur, it 524 
is essential to develop a commonly agreed upon set of diagnostic criteria for LSCD 525 
so that the prevalence of this pathology can be determined and that data developed 526 
among the participating centers can be effectively compared. 527 
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FIGURE LEGENDS 738 
Figure 1. Consort flow diagram. Twenty-eight transplants (23 eyes of 20 patients) 739 
were included and fully assessable at the minimum established period of 6 months. 740 
Eleven (9 eyes, 9 patients) were CLET and 17 (16 eyes, 14 patients) were MSCT.  741 
 742 
Figure 2. Evaluation Endpoints and Final Outcome for Cultured Limbal 743 
Epithelial Transplantation (CLET, N=11) and Mesenchymal Stem Cell 744 
Transplantation (MSCT, N=17). 745 
Panel A shows all clinical signs evaluated with anterior segment slit-lamp 746 
biomicroscopy: ocular (conjunctival) redness, corneal epithelial integrity, and central 747 
corneal epithelial opacity. Boxes extend from the 25th to the 75th percentile, 748 
horizontal bars represent the median, and whiskers extend 1.5 times the length of the 749 
interquartile range (IQR) above and below the 75th and 25th percentiles, 750 
respectively. The mean of each group is shown by black diamonds. Individual values 751 
for each subject are indicated by filled circles. Conjunctival redness and central 752 
corneal epithelial opacity improved significantly from baseline to final evaluation at 12 753 
months. Superficial keratitis improved significantly by 6 months. Both CLET and 754 
MSCT groups improved similarly, except for corneal opacity, which was significantly 755 
better for MSCT at 6 and 12 months (see Table 4 for mean numerical values and 756 
Tables 1 and 2 for individual values). Panel B shows mosaic plots. The area of each 757 
rectangle is proportional to the observed frequency in that cell. Labels show the 758 
conditional relative percentages of each possible epithelial phenotype for each 759 
transplant type at baseline, 6, and 12 months. The number of cases is indicated in 760 
brackets. Mosaic plots represent contingency tables as a matrix of rectangles, the 761 
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dimensions of which are proportional to the observed frequencies of each cross-762 
classification. Cases with conjunctival-like (Conj), corneal-like (Corn), or mixed 763 
phenotypes were divided into the relative proportions across transplant type. CLET 764 
and MSCT performed equally well (no significant differences) regarding this main 765 
objective evaluation outcome. The conjunctival-like phenotype decreased while the 766 
corneal-like phenotype increased over time. Panel C shows the successful outcome 767 
for each type of transplant at each visit (left). Partial success rates are represented 768 
by the lighter-colored area. There were no significant differences between the 769 
percentage of successful cases with CLET or MSCT at 6 months (72.7% vs 76.5%) 770 
or 12 months (77.8% vs 85.7%) months. Kaplan-Meier survival curve analysis (right) 771 
shows a probability of success after CLET of 0.818 (95% CI, 0.6191 to 1.00) at 6 772 
months and of 0.716 (95% CI, 0.488 to 1.00) at 12 months. MSCT survival probability 773 
was 0.812 at 6 months (95% CI, 0.642 to 1.00) and 0.75 at 12 months (95% CI, 774 
0.565 to 0.995). The difference in survival between the two types of cell transplants 775 
was not significant at either of the two periods (log-rank test, p = 0.817). 776 
 777 
Figure 3. This 44-year-old woman (patient No. 10, see Tables 1 and 2) had bilateral 778 
corneal epithelial failure due to 360º limbal stem cell deficiency caused by a 20-year 779 
duration of Stevens-Johnson’s syndrome. Opacity was restricted to the anterior 780 
cornea (epithelium and anterior stroma) and the lens (cataract; not seen in this 781 
photograph). Before entering this trial, she was treated aggressively for her extremely 782 
severe secondary dry eye (a spot of squamous metaplasia can be seen at the lower 783 
inner periphery of her left limbal area) during the course of 6 months. She lost her 784 
first bilateral CLET transplants prematurely (48 h after surgery) due to inadequate 785 
contact lens fitting. After her second bilateral transplants (right eye, CLET; left eye, 786 
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MSCT), her eyelids were maintained closed for 10 days except to quickly deliver 787 
eyedrops, thus keeping the transplants in place. Panels A and B show her right eye 788 
and left eye, respectively, 5 weeks before (upper), 6 months (middle) and 12 months 789 
(lower) after a successful CLET and after a successful MSCT. In vivo confocal 790 
microscopy images of the basal central corneal epithelium showed a mixed epithelial 791 
phenotype before surgery (upper) and corneal-like phenotypes at 6 months (middle) 792 
and 12 months (lower) after both CLET (Panel A) and MSCT (Panel B). Baseline 793 
visual acuity in her right eye was 0.25 (upper) and improved to 0.32 at 6 months 794 
(middle) and 12 months (lower). Baseline visual acuity in her left eye was 0.01 795 
(upper) and improved to 0.25 at 6 months (middle) and to 0.32 after 12 months 796 
(lower). The patient did not want to undergo any other surgery as she was able to 797 
carry on with her life, and we did not encourage further surgery as any trauma in 798 
these patients carries the risk of triggering violent inflammatory relapse. 799 
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TABLES 800 
Table 1. Baseline data (0) and outcomes at 6 months (6) and 12 months (12) after cultivated limbal epithelial transplantation 801 
(CLET) in the 11 assessable cases (9 eyes, 9 patients) suffering from ocular surface failure due to limbal stem cell deficiency 802 
syndrome (LSCD).  803 
CLET 
No./Eye 
Patient No. 
Gender/ 
Age 
LSCD etiology (months 
elapsed till transplant): 
Etiology*/Grade† 
2nd diagnoses SIDEQ 0/6/12 OSDI 0/6/12 VFQ25 0/6/12 
Visual 
Potential‡ 
BCVA 
(ETDRS) 
0/6/12 
Conj 
redness 
(0-4) 
0/6/12 
Central corneal 
epithelial 
opacity (0-4) 
0/6/12 
Corneal 
neovessel area 
(0-4) 
0/6/12 
Corneal 
neovessel 
length (0-4) 
0/6/12 
Corneal 
staining (0-4) 
0/6/12 
Corneal PED 
(0-4) 
0/6/12 
Central corneal 
epithelial 
phenotype (IVCM) 
0/6/12 
Days to AM 
re-absorption 
from surgery 
Final outcome 
6 and 12 months Comments 
1/OD 1/F/49 
Post-infectious keratitis 
(240)+2 previous PKP: 3/T 
Glaucoma 
24/9/16 89.6/ 50.0/65.9 
45.4/ 
57.3/55.0 4 
0.025/ 
0.001/0.001 1/1/1 3/3/3 2/2/1 2/1/1 4/2/1 0/0/0 
Conj/ 
Conj/Conj 24 
Partial success/ 
Partial success 
PKP performed at 
month 18. Although 
remaining clear, vision 
deteriorated due to 
advanced glaucoma 
2/OS 2/F/77 
Persistent corneal ulcer 
(20) 2nd to recurrent 
ocular surface carcinoma 
(120): 3/T 
17/17/13 87.5/ 50.0/60.0 
46.8/ 
49.0/35.3 1 
0.04/ 
0.2/0.25 2/2/1 1/1/0 2/1/1 2/1/1 3/1/0 3/0/0 
Conj/ 
NP/Corn 30 
Partial success/ 
Success 
Patient chronically 
immunosuppressed 
due to heart 
transplant 
3/OD 3/M/47 
Chemical+mechanical 
injury (24): 1/T 
Irreversible retinal 
pathology 
8/6/8 57.5/ 25.0/32.5 
47.1/ 
32.5/34.5 0 
0.001/ 
0.001/0.001 2/2/1 4/3/2 3/1/1 3/2/1 3/2/1 0/0/0 
Conj/ 
Mix/Mix 30 
Success/ 
Success - 
4/OS 7/M/48 Chemical injury (46)+2 previous AMT: 1/T 14/13/- 
62.5/ 
83.3/- 
50.9/ 
43.8/- 4 
0.001/ 
0.001/- 3/2/- 3/3/- 4/3/- 3/3/- 4/3/- 2/1/- 
Conj/ 
Conj/- 90 Partial Success/- 
Regrafted CLET-5, for 
further potential 
improvement 
5/OS 7/M/48 
Chemical injury (54)+2 
previous AMT+previous 
CLET-4: 1/T 
9/8/14 83.3/ 62.5/80.6 
52.9/ 
50.9/55.0 4 
0.001/ 
0.001/0.001 2/1/1 3/2/2 3/3/3 3/2/2 3/1/0 1/0/0 
Conj/ 
Mix/Mix 90 
Success/ 
Success - 
6/OS 9/M/62 
Chemical injury (600)+2 
previous AMT+ PKP: 1/T 
Glaucoma, exotropia 
13/18/- 61.1/ 85.4/- 
53.8/ 
57.0/- 4 
0.001/ 
0.001/- 3/3/- 2/3/- 4/4/- 3/3/- 2/2/- 3/2/- 
Conj/ 
Conj/- 21 Failure/- Regrafted CLET-7 
7/OS 9/M/62 
Chemical injury (608)+2 
previous AMT+previous 
PKP+previous CLET-6: 1/T 
Glaucoma, exotropia 
17/22/16 93.8/ 72.7/85.4 
53.6/ 
53.4/56.0 4 
0.001/ 
0.01/0.01 3/2/2 3/3/2 4/4/4 3/3/3 2/0/0 2/0/0 
Conj/ 
Conj/Conj 30 
Partial success/ 
Partial Success - 
8/OD 10/F/44 
Stevens Johnson+multiple 
AMT (120): 2/T 
Cataract 
28/20/21 100.0/ 93.8/97.5 
47.4/ 
49.8/47.3 2 
0.25/ 
0.32/0.32 3/3/1 3/1/1 3/1/1 3/2/1 2/1/1 0/0/0 
Mix/ 
Corn/Corn 8 
Success/ 
Success - 
9/OD 13/M/48 Chemical injury (84)+3 previous AMT: 1/T 16/11/15 
81.8/ 
72.9/79.2 
30.6/ 
35.8/39.8 4 
0.0001/ 
0.0001/0.0001 2/2/1 4/4/4 4/4/4 4/4/4 0/0/0 0/0/0 
Conj/ 
Mix/Mix 30 
Failure/ 
Failure - 
10/OD 16/M/50 
Graft vs host disease 
(168)+5 previous 
PKP+conj flap+sclera 
patch: 2/T  
17/22/18 87.5/ 90.0/89.6 
56.3/ 
59.1/52.5 0 
0.001/ 
0.001/0.001 4/3/2 4/4/4 4/4/4 4/4/4 0/0/0 0/0/0 
Conj/ 
Conj/Conj 10 
Failure/ 
Failure 
Extremely thin cornea 
under pannus 
prevented its removal 
at surgery. 
Thickness increased so 
as to proceed with a 
keratoprothesis 
11/OS 21/M/41 
Chemical injury (36)+5 
AMT: 1/T 
Cataract, glaucoma 
10/11/9 62.5/ 64.6/87.5 
53.0/ 
55.1/48.4 4 
0.32/ 
0.5/0.4 2/1/1 2/2/2 3/2/1 2/1/1 2/0/0 0/0/0 
Mix/ 
Corn/Corn 34 
Success/ 
Success 
PKP at month 14 
+cataract surgery 
+hard contact lens 
recovered full vision 
Mean (SD)  181.8 (219.2) 
15.7 (6.1)/ 
14.3 (5.8)/ 
14.4 (4.1)- 
78.8 (15.1)/ 
68.2 (20.7)/ 
75.4 (19.8) 
48..9 (7.0)/ 
49.4 (8.8)/ 
47.1 (8.6) 
  - - - - - - - 36.1 (27.9)  - 
Median 
(IQR)  - - - -   
2 (1)/ 2 
(1)/ 1 (0) 
 3 (1)/ 3 (1)/ 2 
(1)  
3 (1)/ 3 (2.5)/ 
1 (3) 
3 (0.5)/ 2 
(1.5)/ 1 (2)   -   - 
Assessable cases were those reaching at least 6 postoperative months; *1: chemical injuries, 2: immune-based inflammatory diseases, 3: non-
inflammatory diseases; †T: total, S: severe; ‡Visual potential: 1, improvement with CLET only (corneal opacity was only superficial); 2, 
improvement with one surgery different form corneal transplant after CLET (i.e. cataract removal); 3, improvement with subsequent corneal 
transplant after CLET (corneal opacity was full thickness); 4, improvement with subsequent corneal transplant plus another surgery (cataract 
removal unless otherwise specified) after CLET, and 0: No possibility of improvement (i.e., due to irreversible retinal pathology); BCVA, Best 
corrected visual acuity; BCVA values 0.01, 0.001, 0.0001, and 0.00001 equivalent to counting fingers, hand motion, light perception, and no 
light perception respectively; ; ETDRS, Early Treatment Diabetic Retinopathy Study; Conj, conjunctival; Corn, corneal; IQR, interquartile range; 
IVCM, in vivo confocal microscopy; SIDEQ, Single Item Dry Eye Questionnaire; VFQ25, National Eye Institute 25-item Visual Function 
Questionnaire  (0-100); OSDI, Ocular Surface Disease Index (0-100); PED, persistent epithelial defect; AMT, amniotic membrane 
transplantation; PKP, penetrating keratoplasty; SD, standard deviation; M, male; F, female; NP: not performed; OS, left eye; OD, right eye. 
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Table 2. Baseline data (0) and outcomes at 6 months (6) and 12 months (12) after bone marrow-derived mesenchymal stem cell transplantation 
(MSCT) in the 17 assessable cases (16 eyes, 14 patients) suffering from ocular surface failure due to limbal stem cell deficiency syndrome 
(LSCD). 
 
MSCT No. /Eye 
Patient Nº 
Gender 
/Age 
LSCD etiology (months elapsed till 
transplant): 
Etiology*/Grade†/ 
2nd diagnoses SIDEQ 0/6/12 OSDI 0/6/12 VFQ25 0/6/12 
Visual 
Potential‡ 
BCVA (ETDRS) 
0/6/12 
Conj redness 
(0-4) 
0/6/12 
Central corneal 
epithelial opacity (0-
4) 
0/6/12 
Corneal 
neovessel: area 
(0-4) 
0/6/12 
Corneal 
neovessel 
length (0-4) 
0/6/12 
Corneal 
staining (0-4) 
0/6/12 
Corneal PED 
(0-4) 
0/6/12 
Central corneal 
epithelial phenotype 
(IVCM) 0/6/12 
Days to AM 
reabsorption from 
surgery 
Final outcome 
6/12 Comments 
1/OS 4/F/31 
 
Chemical injury (24)+ 2 previous 
conj resection+AMT: 1/T 
Cataract 
18/15/8 39.6/ 47.9/64.6 
22.6/ 
43.0/29.4 2 
0.125/ 
0.158/ 
0.125 
1/1/1 1/2/3 3/3/3 2/2/3 2/0/2 1/0/0 Mix/ Conj/Conj 10 
Failure/ 
Failure Poor compliance 
2/OS 6/M/53 
Atopic kerato conjunctivitis (170): 
2/T 
Post-infectious keratitis 
Unsuccessful cataract surgery 
24/23/- 95.8/ 93.8/- 
43.6/ 
41.0- 2 
0.04/ 
0.025/- 3/0/- 2/0/- 3/0/- 2/0/- 1/0/- 0/0/- 
Mix/ 
NP/- 17 
Partial success/ 
- 
Withdrawn at month 7: 
intense systemic flare-up 
worsened both eyes, 
perforating OS cornea; PKP 
required 
3/OD 7/M/48 
Chemical injury (46)+multiple 
AMT: 1/T 
Glaucoma 
12/15/- 77.1/ 85.4/- 
55.0/ 
56.8/- 4 
0.001/ 
0.001/- 3/3/- 3/3/- 4/4/- 4/4/- 3/2/- 0/0/- 
Conj/ 
Conj/- 25 
Failure/ 
- Regrafted MSCT-4 
4/OD 7/M/48 
Chemical injury (54)+multiple 
AMT+previous MSCT-3: 1/T 
Glaucoma, cataract 
9/8/11 83.3/ 62.5/77.8 
54.2/ 
50.9/57.8 4 
0.001/ 
0.001/ 
0.001 
3/2/1 3/2/1 4/4/4 4/3/2 2/2/1 0/0/0 Conj/ Mix/Corn 60 
Success/ 
Success PKP at month 15 
5/OD 8/M/70 
Multiple surgeries for proliferative 
vitreoretinopathy (48): 3/S 
Irreversible macular pathology 
6/3/7 12.5/ 15.6/6.3 
54.6/ 
63.8/62.4 4 
0.001/ 
0.001/ 
0.001 
1/1/0 2/0/1 2/1/1 1/1/1 2/1/1 1/0/0 Mix/ Corn/Corn 10 
Success/ 
Success PKP at month 30 
6/O 10/F/44 
Stevens Johnson 
(120)+multiple AMT: 2/T 
Cataract 
28/23/16 100..0/ 93.8/97.5 
46.1/ 
49.3/41.8 2 
0.01/ 
0.25/ 
0.32 
3/3/1 4/3/1 4/3/2 3/2/1 3/2/2 0/0/0 Mix/ Corn/Corn 8 
Success/ 
Success - 
7/OS 11/F/37 Congenital aniridia (132): 3/S Cataract, nystagmus 16/14/12 
38.9/ 
45.5/63.6 
39.3/ 
41.6/43.3 4 
0.062/ 
0.1/0.1 1/0/0 4/3/2 3/2/1 2/2/2 0/0/0 0/0/0 
Conj/ 
Mix/Mix 22 
Success/ 
Success - 
8/OD 12/F/42 
Atopic kerato conjunctivitis 
(132)+2 previous AMT: 2/T 
Cataract 
21/20/- 79.2/ 77.1/- 
39.2/ 
40.2/- 2 
0.031/ 
0.025/- 1/2/- 1/1/- 2/2/- 2/2/- 1/1/- 0/0/- 
Conj/ 
Conj/- 15 
Failure/ 
- Regrafted MSCT-9 (Table 2) 
9/OD 12/F/42 
Atopic kerato conjunctivitis 
(140)+2  
previous AMT+previous MSCT-
8: 2/T 
Cataract. 
17/21/23 66.7/ 66.7/75.0 
33.9/ 
39.7/27.8 2 
0.05/ 
0.05/ 
0.05 
2/2/1 1/1/1 2/2/2 2/2/2 1/1/1 0/0/0 Conj/ Conj/Conj 15 
Failure/ 
Failure 
Poor compliance 
Systemic disease poorly 
controlled 
10/O 14/F/53 Congenital aniridia (160): 3/S Cataract, nystagmus, glaucoma 21/20/21 
83.3/ 
75.0/85.4 
44.7/ 
43.8/47.8 2 
0.1/ 
0.08/ 
0.08 
1/1/0 2/1/1 2/1/1 2/1/1 3/1/0 0/0/0 Mix/ Corn/Corn 28 
Success/ 
Success 
Had a previous CLET (lost 
transplant No. 7) 
Cataract surgery at month 
20 did not recover vision 
11/OD 17/F/28 
Chemical injury (72)+previous 
cadaveric limbal transplant 
+AMT+PKP: 1/T 
Severe perennial allergic 
conjunctivitis, cataract.  
19/13/13 64.6/ 33.3/33.3 
40.3/ 
35.8/46.8 4 
0.01/ 
0.01/ 
0.01 
3/2/1 1/1/1 4/4/4 3/2/2 1/1/0 0/1/0 Conj/ Mix/Conj 20 
Partial success/ 
Partial success PKP at month 13 
12/OD 18/M/65 
Chemical injury (360)+previous 
AMT+PKP+intracorneal rings: 1/T 
Cataract 
24/16/16 81.3/ 70.8/79.2 
44.1/ 
33.6/37.2 4 
0.12 
0.5/0.4 2/1/1 1/1/1 3/3/3/ 2/2/2 2/0/0 0/0/0 
Mix/ 
Corn/Corn 29 
Success/ 
Success PKP at month 20 
13/OS 19/F/49 Chemical injury (80)+oral mucosal transplant+2 AMT: 1/S 23/19/18 
91.7/ 
97.9/83.3 
37.5/ 
48.8/38.6 3 
0.01/ 
0.2/0.2 1/1/1 2/1/0 2/1/1 2/1/1 1/0/0 0/0/0 
Conj/ 
Corn/Corn 20 
Success/ 
Success PKP at month 24 
14/OS 20/F/44 
Stevens Johnson (90)+3 previous 
AMT: 2/T 
Cataract 
23/16/21 83.3/ 62.5/81.3 
46.1/ 
47.8/42.5 4 
0.158/ 
0.5/0.32 3/2/2 2/2/1 2/2/2 1/1/1 4/3/1 0/0/0 
Mix/ 
Corn/Corn 15 
Success/ 
Success Cataract progression 
15/OD 21/M/41 
Chemical injury (45)+5 previous 
AMT+PKP: 1/T 
Cataract, glaucoma 
9/12/7 64.6/ 64.6/70.8 
44.0/ 
33.6/48.0 4 
0.01/ 
0.01/ 
0.001 
4/3/2 4/2/1 4/3/3 3/2/1 4/NP/1 4/2/0 Conj/ Conj/Mix 85 
Partial success/ 
Success 
Initially performed for 
impending perforation 
16/OD 22/M/54 
Chemical injury (84)+2 previous 
AMT: 1/T 
Cataract 
20/18/7 70.8/ 66.7/89.6 
40.6/ 
21.7/36.3 3 
0.25/ 
0.25/ 
0.25 
2/1/1 1/0/0 1/1/1 2/1/1 0/0/0 0/0/0 Mix/ Corn/Corn 30 
Success/ 
Success - 
17/OS 22/M/54 
Chemical injury (95)+3 previous 
AMT: 1/T 
Cataract 
28/22/19 77.1/ 70.8/56.3 
37.0/ 
34.4/33.6 4 
0.001/ 
0.001/ 
0.001 
4/2/1 4/4/3 4/4/4 3/3/2 3/1/0 3/0/0 Conj/ Conj/Conj 60 
Partial success/ 
Partial success - 
Mean (SD)  108.9 (77.8) 18.7 (6.5)/ 16.4 (5.4)/ 14.2 (5.7) 
71.2 (22.5)/ 66.5 
(21.8)/ 68.9 (24.0) 
42.5 (8.0)/ 42.7 
(9.9)/ 42.4 (9.8)   - - - -    
 
27.6 (21.1)   
Median 
(IQR)   - - - - - 
2 (2)/ 2 (1)/ 1 
(0) 
2 (2)/ 1 (1)/ 1 
(0) 
3 (2)/ 2 (2)/ 
2 (2) 
2 (1)/ 2 (1)/ 
1.5 (1)   -  -  
Assessable cases were those reaching at least 6 postoperative months; *1: chemical injuries, 2: immune-based inflammatory diseases, 3: non-
inflammatory diseases; †T: total, S: severe; ‡Visual potential: 1, improvement with CLET only (corneal opacity was only superficial); 2, 
improvement with one surgery different form corneal transplant after CLET (i.e. cataract removal); 3, improvement with subsequent corneal 
transplant after CLET (corneal opacity was full thickness); 4, improvement with subsequent corneal transplant plus another surgery (cataract 
removal unless otherwise specified) after CLET, and 0: No possibility of improvement (i.e. due to irreversible retinal pathology); BCVA, Best 
corrected visual acuity; BCVA values 0.01, 0.001, 0.0001, and 0.00001 equivalent to counting fingers, hand motion, light perception, and no 
light perception respectively; Conj, conjunctival; Corn, corneal; IQR, interquartile range; IVCM, in vivo confocal microscopy; VFQ25, National 
Eye Institute 25 Visual Function Questionnaire (0-100); OSDI, Ocular Surface Disease Index (0-100); SIDEQ, Single Item Score Dry Eye 
questionnaire (0-28); AMT, amniotic membrane transplantation; PED, persistent epithelial defect; PKP, penetrating keratoplasty; SD, standard 
deviation; M, male; F, female; NP, not performed; OS, left eye; OD, right eye. 
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Table 3. Ocular Surface Clinical Signs Evaluated to Define and Grade Limbal Stem Cell Deficiency and Score the Evaluation End-806 
Points. 807 
  
 
 
 
Conjunctival 
Redness*+ 
 
 
Central 
Corneal 
Epithelial 
Opacity* 
Corneal Epithelial Integrity 
Corneal 
Superficial Neo 
Vascularization 
Area/Length* 
Visual Prognosis and Potential for Visual Recovery  
 
 
Central Corneal Phenotype (In Vivo Confocal 
Microscopy)† 
Superficial 
Punctate Keratitis* 
Epithelial 
Ulceration Area* 
 
 
Previous Ocular Media Opacity 
Surgeries Judged 
Necessary to Recover Full 
Potential Vision 
Grade 0 
White 
conjunctiva 
None 
 
None 
None  
/None 
Any grade of corneal opacity plus 
non-corneal irreversible visual loss 
(e.g., irreversible retinal pathology, 
advanced glaucoma) 
No potential for gain: Stem 
cell transplant performed to 
deal with pain and avoid 
globe removal 
CORNEAL: 
Regular, hexagonal cells with a cell diameter 
<20 µm; dark cytoplasm, dark nucleus; hyper-
reflective, bright well-defined cell margins. 
 
Grade 1 
Widening of the 
vessels 
Mild: clearly 
visible pupil 
 
≤¼ 
≤¼  
/ 1mm 
Corneal opacity restricted to 
anterior cornea (and anterior 
stroma) 
One surgical procedure: stem 
cell transplant only 
CONJUNCTIVAL: 
Closely packed round or irregularly shaped 
cells; cell diameter of >20 µm (irregular size); 
large nucleus/cytoplasm ratios; dark cytoplasm 
and bright, hyperreflective nucleus with ill-
defined cell margins. 
Occasional goblet cells 
Grade 2 Mild redness 
Moderate: 
hazily visible 
pupil  
>¼ and ≤½ 
>¼ and ≤½  
/ 2-3 mm 
Corneal opacity restricted to 
anterior cornea (as Grade 1) plus 
another non-corneal reason for 
visual loss (e.g., cataract) 
Two surgical procedures: 
stem cell transplant + non-
corneal surgery (e.g., 
cataract removal) 
MIXED: 
Both corneal and conjunctival phenotypes are 
present 
Grade 3 
Moderate 
redness 
Severe: 
faintly visible 
pupil  
>½ and ≤¾ 
>½ and ≤¾  
/ 4-5 mm 
Full thickness corneal opacity Two surgical procedures: 
stem cell transplant + corneal 
transplant 
 
Grade 4 
Intense 
redness 
Severe: no 
visible pupil 
 
>¾ 
>¾  
/ ≥6 mm 
Full thickness corneal opacity plus 
another non-corneal reason for visual 
loss (e.g., cataract) 
Three surgical procedures: stem 
cell transplant + corneal 
transplant + non-corneal surgery 
(e.g. cataract removal) 
 
*Evaluated by slit-lamp biomicroscopy. 
+ Evaluated following the Efron Scale for conjunctival redness.64 
†Evaluated with the Heidelberg Retinal Tomograph HRT-3 and Rostock Cornea Module (HRT3, Heidelberg Engineering 
GmbH, Heidelberg, Germany). 
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Table 4. Characteristics, Endpoint Values, and Outcome of the 28 Assessable Cases 808 
(23 eyes from 20 patients) of Corneal Epithelial Failure Due to Limbal Epithelial Stem 809 
Cell Deficiency Randomized to Cultivated Limbal Epithelial Transplantation (CLET) or 810 
Mesenchymal Stem Cell Transplantation (MSCT). 811 
CHARACTERISTIC / ENDPOINT CLET (N = 11) MSCT (N = 17) p-
values* 
Females/Males ─ no. (%); 95% confidence 
interval (CI) 
3 (27.3); 7.3 to 60.7/ 
8 (72.7); 39.1 to 92.7 
9 (52.9); 28.5 to 76.1/ 
8 (47.1); 23.9 to 71.5 
0.2530 
Age ─ years (mean±SD) 52.4±10.5 47.2±10.8 0.3448 
Limbal Stem Cell Deficiency    
Grade: Total/ Severe ─ no. (%), 95% CI 11 (100) /0 (0) 13 (76.5); 49.8 to 92.2/ 
4 (23.5); 7.8 to 50.2 
0.1324 
Etiology ─ no. (%); 95% CI    
Chemical Burns ─16 (57.1) 7 (63.6); 31.6-87.6 9 (52.9); 28.5 to 76.1 0.8669 
Immune-based Inflammatory Diseases 
─ 7 (25.0) 
2 (18.2); 3.2 to 52.3 5 (29.4); 11.4 to 56 0.8232 
Non-inflammatory Diseases, Other ─ 5 
(17.9) 
2 (18.2); 3.2 to 52.3 3 (17.7); 4.7 to 44.2 1 
Months from Disease Onset to Cell 
Transplant ─ mean±SD 
181.8±219.2 108.9±77.8 0.9437 
Days from Cell Transplant to Supporting 
Amniotic Membrane Reabsorption ─ 
mean±SD 
36.1±27.9 27.6±21 0.1634 
Primary Evaluation End-Points 
Baseline/ 6 months/ 12 months 
   
Symptoms/Quality of Life* Questionnaires 
(range) ─ mean±SD 
   
Single Item Dry Eye Questionnaire 
SIDEQ (0-28) 
15.7±6.1/ 14.3±5.8/ 14.4±4.1 18.7±6.5/ 16.4±5.4/ 14.2±5.7 
p=0.0237and p=0.0336 between 
baseline and 6 or 12 months 
0.2379/ 
0.3408/ 
0.9178 
Ocular Surface Disease Index OSDI 
(0-100; severe>32) 
78.8±15.1/ 68.2±20.7/ 75.4±19.8 
p=0.0318 and p=0.0072 between 
baseline and 6 or 12 months 
71.2±22.5/ 66.5±21.8/ 68.9±24 0.4795/ 
0.8352/ 
0.4306 
National Eye Institute 25-item Visual 
Function Questionnaire NEI-VFQ25 
(0-100) 
48.9±7/ 49.4±8.8/ 47.1±8.6 42.5±8/ 42.7±9.9/ 42.4±9.8 0.0239/ 
0.0774/ 
0.2524 
Clinical signs (range) ─ median 
(interquartile range [IQR]) 
   
Conjunctival redness (0-4) 2 (1)/ 2(1)/ 1 (0) 
p=0.0012 between baseline and 12 
months 
2 (2)/ 2(1)/ 1 (0) 
p<0.0001 between baseline and 12 
months 
0.6057/ 
0.2638/ 
0.2438 
Central corneal epithelial opacity (0-4) 3 (1)/ 3 (1)/ 2 (1) 
p=0.0129 between baseline and 12 
months 
2 (2)/ 1 (1)/ 1 (0) 
p=0.0023 between baseline and 12 
months 
0.1323/ 
0.0275/ 
0.04 
Corneal epithelial integrity: superficial 
punctate keratitis (0-4) 
2 (1)/ 1 (2)/ 0 (1) 
p=0.0428 and p=0.0012 between 
baseline and 6 or 12 months 
2 (2)/ 1 (1.25)/ 0.5 (1) 
p=0.0263 and p=0.0006 between 
baseline and 6 or 12 months 
0.4693/ 
0.7356/ 
0.3532 
Corneal epithelial integrity: persistent 
epithelial defect or ulceration (0-4) 
0 (2)/ 0 (0)/ 0 (0) 0 (0)/ 0 (0)/ 0 (0) 0.2558/ 
0.3422/ 
1 
Epithelial phenotype in central cornea (in 
vivo confocal microscopy) ─ no. (%); 95% 
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CI 
Conjunctival phenotype 
18 (64.3)/ 11 (42.3)/ 7 (30.4) 
9 (81.8); 47.8 to 96.8/ 
5 (50); 23.7 to 76.3/ 
3 (33.3); 9 to 69.1 
9 (52.9); 28.5 to 76.1/ 
6 (37.5); 16.3 to 64.1/ 
4 (28.6); 9.6 to 58 
0.2486/ 
1/ 
0.2486 
Mixed phenotype 
10 (35.7)/ 6 (23.1)/ 5 (21.7) 
2 (18.2); 3.2 to 52.3 / 
3 (30); 8.1 to 64.6/ 
3 (33.3); 9 to 69.1 
8 (47.1); 23.9 to 71.5/ 
3 (18.8); 5 to 46.3/ 
2 (14.3); 2.5 to 43.9 
1/ 
0.4915/ 
0.5735 
Corneal phenotype 
0 (0)/ 9 (34.6)/ 11 (47.8) 
0 (0); 0 to 32.2/ 
2 (20); 3.5 to 55.8/ 
3 (33.3); 9 to 69.1 
0 (0); 0 to 22.9/ 
7 (43.8); 20.8 to 69.5%)/ 
8 (57.1); 29.7 to 81.2 
0.8261/ 
0.4152/ 
0.854 
Secondary Evaluation End-Points ─ 
baseline/ 6 months/ 12 months 
   
Corneal neovessels: area (0-4) ─ median 
(IQR) 
3 (1)/ 3 (2.5)/ 1 (3) 
p=0.0129 between baseline and 12 
months 
3 (2)/ 2 (2)/ 2 (2) 
p=0.0307 and p=0.0045 between 
baseline and 6 or 12 months 
0.3197/ 
0.594/ 
0.8416 
Corneal neovessels: length (0-4) ─ 
median (IQR) 
3 (0.5)/ 2 (1.5)/ 1 (2) 
p=0.0307 and p=0.0044 between 
baseline and 6 or 12 months 
2 (1)/ 2 (1)/ 1.5 (1) 
p=0.0055 between baseline and 12 
months 
0.074/ 
0.2271/ 
0.7037 
Best-corrected visual acuity: all cases† ─ 
mean±SD 
0.06±0.11/ 0.09±0.17/ 0.11±0.16 0.06±0.07/ 0.13±0.16/ 0.13±0.14 0.148/ 
0.1171/ 
0.3668 
Best-corrected visual acuity: successful 
cases† ─ mean±SD 
0.08±0.13/ 0.13±0.19/ 0.14±0.18 0.06±0.08/ 0.15±0.18/ 0.14±0.15 0.6837/ 
0.4592/ 
0.9307 
SUCCESSFUL OUTCOME 
6 months/ 12 months ─ no. (%); 95% CI 
8 (72.7); 39.3 to 92.7/ 
7 (77.8); 40.2 to 96.1 
13 (76.5); 49.8 to 92.2/ 
12 (85.7); 56.2 to 97.5 
0.8232/ 
0.6241 
 812 
* Between CLET and MSCT groups. Significant p-values are highlighted in bold characters. 813 
Only significant P-values are shown in the 2nd (CLET) and the 3rd (MSCT) columns. 814 
†Only one case, CLET nº2 (Table 1), had a grade 1 potential to recover visual acuity, 815 
meaning that it was previously considered that her damage was restricted to the corneal 816 
epithelium. Her visual acuities were 0.04, 0.2 and 0.25 at baseline, 6, and 12 months, 817 
respectively.  818 
 819 
 820 
 821 
 822 
 823 
 824 
 825 
 826 
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Table 5. Serious and Non-serious Adverse Events Encountered in All Cell Transplants 827 
Performed (N = 37), Including 9 Transplants that Did Not Reach the Minimum 828 
Established 6 Months of Follow Up (5 CLET and 4 MSCT) Plus the 28 That Did (11 829 
CLET and 17 MSCT)*. 830 
EVENT CLET (N = 16) MSCT (N = 21) 
 No. of Events (%)/ 
Transplant-Patient 
No./ Baseline 
Disease/ Immuno- 
suppressants 
Relation to Study 
medication (Cell 
Transplant)/ 
Severity/ 
Attributable 
Relation 
Final 
Outcome/ 
Comments 
No. of Events (%)*/ 
Transplant-Patient 
No./ Baseline 
Disease/ Immuno-
suppressants 
Relation to Study 
Medication (Cell 
Transplant)/ 
Severity/ 
Attributable 
Relation 
Final 
Outcome/ 
Comments 
Serious 
adverse 
events 
      
Herpes 
simplex 
keratitis 
   
1 (2.7)/ 8-15/ 
Persistent corneal 
ulcer due to herpes 
simplex keratitis/ 
Mycophenolate 
mofetyl 
Unrelated/ 
Moderate/ 
Recurrence of 
baseline disease, 
facilitated by 
surgical trauma 
and/or immuno 
suppression used 
Solved with 
sequelae/ 
Penetrating 
corneal 
transplant 
performed 
due to risk of 
perforation 
Corneal 
perforation 
   1 (2.7)/ 2-6/ Atopic 
keratoconjunctivitis 
secondary to severe 
atopic dermatitis/ 
Cyclosporine+ 
azathioprine 
Unrelated/ 
Severe/ Intense 
relapse of 
baseline disease, 
already poorly 
controlled 
systemically 
Solved with 
sequelae/ 
Tectonic 
corneal 
transplant 
Ocular 
surface 
neoplasia 
1 (2.7)/ 2-2/ 
Moderate/ 
Persistent corneal 
ulcer due to ocular 
surface neoplasia 
and its required 
treatments/ 
Cyclosporine+ 
azathioprine 
Unrelated/ 
Moderate/ 
Recurrence of 
baseline disease 
at same rate as 
before cell 
transplant (patient 
long-term immuno 
suppressed due 
to previous heart 
transplant) 
Solved 
(excisional 
surgery) with 
no sequelae/ 
Cell transplant 
action was not 
interrupted as 
persistent 
corneal 
wound healed 
   
Non-serious 
adverse 
events† 
      
Loss of 
transplant 
within 24 hr 
after 
surgery 
(Not 
assessable 
at first 
evaluation) 
1 (2.7)/ 4-5/ Severe/ 
Chemical injury/ 
mycophenolate 
mofetil 
Unrelated/ 
Baseline disease? 
(same fate for all 
previous ammiotic 
membranes 
grafts) 
Unsolved with 
no sequelae/ 
No further 
actions taken; 
patient was 
withdrawn 
3 (8.1)/ 1,2,3-5/ 
Severe/ Chemical 
injury/ 
mycophenolate 
mofetil 
Unrelated/ 
Severe/ Baseline 
disease (same 
fate for all 
previous amniotic 
membrane grafts) 
Unsolved 
with no 
sequelae/ 
No further 
actions 
taken; 
patient was 
withdrawn 
Loss of 
transplant 
within 48 hr 
after 
4 (10.8)/4, 6-14; 7-
14; 9-19/ Severe/ 
Stevens-Johnson 
(No. 5, 6); 
Unrelated/ 
Severe/ Bandage 
contact lens 
displacement? 
Solved with o 
sequelae (all 
regrafted 
successfully) 
   
44 of 44 
surgery congenital aniridia 
(No. 7); chemical 
injury (No. 9)/ 
Cyclosporine (No.5, 
6); azathioprine 
(No. 7); 
mycophenolate 
mofetil (No. 9) 
Corneal 
erosion 
   2 (5.4)/ 14-20/ 
Moderate/ Stevens-
Johnson’s 
syndrome/ 
Micophenolate 
mofetil 
Unrelated/ Mild/ 
Misdirected 
lashes rubbing 
cornea due to 
underlying 
disease 
Solved with 
no sequelae/ 
Lashes were 
removed 
permanently 
Flu episode    1 (2.7)/ 10-14/ 
Moderate/ 
Congenital aniridia/ 
azathioprine 
Unrelated/ Mild/ 
Patient was not 
vaccinated 
Solved with 
no 
sequelae/ 
no effect in 
transplant 
* CLET, cultivated limbal epithelial transplantation; MSCT, mesenchymal stem cell 831 
transplantation. 832 
† Non-serious adverse events shown are those that were moderate or severe. The 833 
remaining non-serious adverse events were mild, easily solved and all were 834 
considered to be unrelated with cell transplant: nausea, vomiting, pharyngitis, twisted 835 
ankle, and reconstruction of anophthalmic socket to improve existent cosmetic 836 
prosthesis in the contralateral eye. Three patients complained of mild asthenia and 837 
their mycophenolate mofetil was lowered to 1.5 d/day in one patient and to 1 mg/kg in 838 
2 more patients. Two patients had transient blood pressure mild elevation that was 839 
brought under control by lowering their cyclosporine dose from 5 to 3 mg/kg/day.840 
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Supplemental Methods  
Preparation of amniotic membrane 
Human amniotic membranes (2.5x2.5 cm) were used as carriers for cells, and they were prepared 
using our previously described method.1 Briefly, the membranes were stored at -80ºC upon arrival. 
Immediately before use, they were thawed, washed with phosphate buffered saline (PBS, Life 
Technologies-Gibco, Carlsbad, CA, USA), treated with trypsin for 15 min at room temperature, and 
gently scraped to remove the epithelial cells from the underlying basement membrane. Afterwards, 
the samples were washed twice in PBS to remove cellular debris to obtain the de-epithelialized 
amniotic membranes. Each amniotic membrane was attached to the bottom of a 35-mm cell culture 
dish with the basement membrane side up. The quality criteria for the amniotic membrane were as 
follows: (1) minimum size to almost cover a 35-mm diameter culture plate, (2) tissue sterility, (3) 
tissue integrity, and (4) adherence to the plate.  
 
Preparation of cultivated limbal epithelial cells for transplantation (CLET) 
Cadaveric limbal rings were preserved within 7 days from donor death, and they were processed 
during the 4 h after arrival following a modification of our previously reported protocols.1,2 Briefly, two 
2x2 mm pieces of limbal tissue (limbal explants) were extracted from limbal ring, and both were 
plated onto the de-epithelialized amniotic membranes (2.5x2.5 cm). The limbal explants were 
maintained initially under a drop of fetal bovine serum (FBS) (Life Technologies-Gibco) in standard 
conditions of 37ºC, 95% humidified air, and 5% CO2 gas mixture. After 24 h, 3 ml of the following 
culture medium were added: DMEM/F12 media (1:1 mixture) (Life Technologies-Gibco), 5% FBS 
(Life Technologies-Gibco), 50 µg/ml hydrocortisone (Sigma Aldrich, St. Louis, MO, USA), 0.5 ng/ml 
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cholera toxin (Gentaur, Kampenhout, Belgium), 5 ng/ml insulin-transferrin-selenium (ITS) (Sigma 
Aldrich), 0.5% dimethylsulfoxide (Sigma Aldrich), 2.5 ng/ml human epidermal growth factor (Life 
Technologies-Gibco), and 0.5 mg/ml gentamicin (Life Technologies-Gibco). The limbal explants were 
kept in culture until a cellular outgrowth front of approximately 2 mm was present, and then they were 
removed to allow further cell proliferation until cells reached 90% confluence (3-4 weeks). The mean 
time for explant removal was 12.18 ± 1.17 days (mean ± standard error of the mean, SEM). The 
culture medium was changed every 3 days. The quality criteria for the limbal explants were as 
follows: (1) 2x2 mm size, (2) tissue sterility, (3) adherence to the amniotic membrane, and (4) 
appearance of cell outgrowth in less than 15 days. 
 
Preparation of bone marrow-derived mesenchymal stem cells for transplantation (MSCT) 
Bone marrow was processed as we previously reported,3,4 obtaining 20-200x106 of mesenchymal 
stem cells from every donor after 2 weeks of culture. Subsequently, the mesenchymal stem cells 
were characterized following the International Society for Cellular Therapy (ISCT) position 
statement.3,5,6 Expression of the positive markers CD73, CD90, CD105, and CD166 and the negative 
markers CD14, CD34, CD45, and HAD-DR was analyzed by flow cytometry. In addition, cell viability 
was studied by trypan blue staining. Data were reported as means ± SEMs. For MSCT use, 100,000 
fresh cells (passage 2) were seeded in a drop of FBS onto a 2.5x2.5 cm piece of de-epithelized 
amniotic membrane. After 2 h, 2 ml of DMEM medium (High glucose; Life Technologies-Gibco) 
containing 20% FBS (Life Technologies-Gibco), and 0.5 mg/ml gentamicin (Life Technologies-Gibco) 
were added, and incubation continued at 37ºC, 95% humidified air, and 5% CO2 gas mixture until 
cells achieved 90% confluence (3-5 days) The culture medium was changed every 3 days.  
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Immunofluorescence microscopy 
Amniotic membrane-cell grafts, with either cultivated epithelial limbal cells or mesenchymal stem 
cells, were monitored under a phase contrast microscope (Eclipse TS100, Nikon, Tokyo, Japan) and 
fixed with 4% formaldehyde (Panreac, Barcelone, Spain). Before immunofluorescence assays, each 
amniotic membrane-cell graft was cut into 5 pieces of about 1 cm2 each. Immunofluorescence assays 
were performed following a previously reported protocol.2 The samples were permeabilized for 10 min 
with 0.3% Triton X-100 (Sigma-Aldrich), blocked with 5% donkey serum (Sigma-Aldrich) for 1 h at 
room temperature, and incubated overnight at 4ºC with specific primary antibodies (Table S1). 
Subsequently, samples were incubated 1 h at room temperature with the corresponding secondary 
antibody (Alexa Fluor® 488 donkey anti-mouse 1:200 or donkey anti-rabbit 1:300; Life Technologies). 
Cell nuclei were counterstained with propidium iodide (1:6,000; Life Technologies). Each piece 
obtained from a single amniotic membrane-cell graft was incubated with one primary antibody. The 
marker analyzed in each piece was randomly assigned. Regarding the total number of experiments 
performed, the same marker was analyzed in different areas of the total amniotic membrane-cell graft 
surface (near the explant or at the graft edge). Images were acquired with an inverted fluorescence 
microscope (DM4000B, Leica, Wetzlar, Germany). The percentage of positive cells was estimated for 
each marker. Negative controls included the omission of primary antibodies. All antibodies were 
previously validated in different positive controls by our research group.2,7 At least four samples from 
different cell donor were analyzed for each condition (n=4). 
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Patients  
Prior to the initiation of these procedures, all patients and all allogeneic tissue donors underwent 
mandatory screening for the following transmittable diseases: human immunodeficiency virus, human 
T-cell leukemia-lymphoma virus, syphilis, and hepatitis B-C.  
For transplantation surgery, retrobulbar anesthesia was achieved with 3 cc of 5% lidocaine (Lidocaine 
Braun®, Braun Medical SA, Mensungen, Germany). First, a conjunctival peritomy was performed and 
tissues were recessed, leaving the sclera bare. Fibrovascular pannus, if present, was scraped and 
removed from the recipient cornea extending to the limbal area, allowing a gentle 360° limbal 
peritomy to be performed. The scraped surface was polished with a diamond bur, and bleeding 
vessels were cauterized. Then the CLET or MSCT graft was carefully lifted from the culture dish and 
placed with the cells facing the recipient ocular surface. The graft was then sutured to the perilimbal 
episclera, 2-4 mm posterior to the limbus, with 8 interrupted 10-0 nylon stitches. Topical eyedrops 
(see below) were then applied, and an 18-22 mm diameter bandage contact lens was set in place, 
and the eye was patched for 24 h.  
Twenty-four hours after surgery, each patient was evaluated and topical treatment with the fixed 
combination of 1% prednisolone acetate and 0.3% tobramycin (Tobradex®, Alcon Laboratories, FT. 
Worth, TX, USA) was prescribed 4 times per day until the amniotic membrane dissolved. The stitches 
and the contact lens were also removed between 4 and 6 weeks. Then, 1 mg/ml dexamethasone 
(Maxidex®, Alcon Laboratories) was instilled 4 times a day and slowly tapered in the next 3 months.  
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Evaluation end-points 
Limbal stem cell deficiency-related symptoms and their impact on daily life activities were evaluated 
with three self-administered questionnaires. The Single Item Dry Eye Questionnaire (SIDEQ) gives a 
0-4 score to each of 5 different questions about the presence of dryness, foreign body sensation, 
burning/stinging, pain, itching, sensitivity to light, and blurred vision (maximum score: 28); the Ocular 
Surface Disease Index (OSDI) also evaluates ocular surface symptoms with 12 questions, and scores 
>12 indicate abnormal symptomatology, and >32 means severe symptoms (maximum score 100).8 
The visual function-related aspects of the quality of life were evaluated with The National Eye Institute 
25-item Visual Function Questionnaire (NEI-VFQ25), where higher scores on a 0 to 100 scale 
indicate better function.9 
Right after the questionnaires were administered, best corrected visual acuity was measured using 
the standard Early Treatment Diabetic Retinopathy Study (ETDRS), as is mandatory in clinical trials. 
It is crucial to note that vision improvement is never the primary goal of this kind of cell transplantation 
because this technique intends only to reconstruct the corneal epithelium. It will not affect deeper 
corneal opacification, cataract, glaucoma that often accompanies these pathologies, or other potential 
causes of diminished vision such as concomitant retinal pathology in post-multiple surgery cases, 
nystagmus in congenital aniridia, and others. For these conditions, if they are not irreversible, other 
visual rehabilitation techniques might be needed after CLET or MSCT. To avoid misinterpretation by 
the patient, the potential dependence of the visual prognosis on the surgical procedures judged to be 
necessary to restore vision after cell transplantation was explained at the initial visit and given a 
grade as shown in Table 1. 
After determination of the best corrected visual acuity, the ocular surface clinical status was evaluated 
as routinely done by anterior segment biomicroscopy using a slit lamp and taking photographs 
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(IMAGENet program Fuji Fujifilm Finepix S1 Pro. Fuji Photo Film Co., LTD., Tokyo, Japan; Slit lamp 
Topcon SL-8Z, Topcon Corp., Hasunuma-cho, Habasi-ku, Tokyo, Japan) at each visit. All evaluated 
parameters at the initial visit and at 6 and 12 months after transplantation and associated scales are 
shown in Table 1. Ocular redness was evaluated in the bulbar conjunctiva, proximal to the cornea. 
Nasal and temporal areas were assessed independently based on the Efron scale (score 0-4),10 and 
the final score was obtained after averaging both values. Corneal epithelial integrity was evaluated 
with the vital stain sodium fluorescein using a commercial strip previously wetted and applied to the 
inferior fornix. After 2 min, the degree of staining was recorded using a cobalt blue filter (Topcon 
Corp., Tokyo, Japan) over the light source of the slit-lamp biomicroscope and a yellow Wratten #12 
filter (Eastman Kodak, Rochester, NY, USA). Both superficial punctuate keratitis (Oxford scheme, 0-5 
score)11 as well as the potential presence of persistent epithelial defect were recorded.  
In vivo laser confocal microscopy was the last-performed evaluation end-point (always by same 
coauthor IP). We used the Heidelberg Retinal Tomograph HRT-3 and Rostock Cornea Module 
(HRT3, Heidelberg Engineering GmbH, Heidelberg, Germany) and followed the protocol as 
previously described.1 Topical anesthesia was achieved with 0.1% tetracaine chlorhydrate and 0.4% 
oxibuprocaine chlorhydrate solution (Colircusí Anestésico Doble®, Alcon Laboratories) Optical 
sections from the central cornea were taken at all layers of the epithelium, and the basal layers were 
then evaluated for the defined phenotypes, as explained in Table 1. 
Several other tests were performed at the initial visit and at 6 and 12 months that were not related to 
outcomes but are part of any routine ophthalmic evaluation. Schirmer test without topical anesthesia 
evaluated tear production. One Schirmer sterile strip (Tearflo; HUB Pharmaceuticals LLC, Rancho 
Cucamonga, CA, USA), was placed in the lateral canthus of the inferior lid margin. The length of 
wetting was measured after 5 min, with eyes closed. Intraocular pressure was evaluated using a 
Perkins tonometer (Perkins MK 2; HS Clemens Clarke International, Essex, United Kingdom). Fundus 
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evaluation was by indirect ophthalmoscopy under pharmacologic pupil dilation. When media opacity 
prevented visualization of intraocular structures by slit-lamp examination or funduscopy, anterior 
segment optical coherence tomography (OCT) and posterior segment echography (ultrasound) were 
routinely performed. 
During the course of all visits, patients were carefully questioned for potential medication side-effects 
or any other possible adverse event by two clinicians (co-authors MC and JMH) who also evaluated 
clinical parameters independently. In case of disagreement, the average score was recorded.  
 
Supplemental Results  
Characterization of bone marrow-derived mesenchymal stem cells 
Bone marrow-derived mesenchymal stem cells had the phenotype defined by the ISCT. The positive 
markers CD73, CD90, CD105 and CD166 were expressed by 99.7 ± 0.1%, 99.9 ± 0.02%, 97.8 ± 
0.5%, and 98.98 ± 0.31% of the cells, respectively. Negative markers CD14, CD34, CD45 and HLA-
DR were expressed by 0.1 ± 0.04%, 0.03 ± 0.02%, 0.09 ± 0.03%, and 0.05 ± 0.02% of the cells, 
respectively. The viability of the bone marrow-derived mesenchymal stem cells was 98.6 ± 0.002%. 
 
Immunofluorescence microscopy 
Protein markers K15 and p63alpha for limbal epithelial cells and K3 for differentiated corneal 
epithelial cells were analyzed in both types of cells cultured on amniotic membrane. The percentage 
of limbal epithelial cells positive for limbal stem cell markers K15 and p63alpha was 90% and 70% 
respectively (Figure S1 and Table S2). The corneal differentiated epithelial protein K3 was expressed 
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by 80% of limbal cells (Figure S1 and Table S2). These markers K15, p63alpha, and K3 were 
expressed by 90% of mesenchymal stem cells cultured on amniotic membrane (Figure S1 and Table 
S2).  
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Supplemental Tables 
 
Table S1. Primary antibodies used for immunodetection assays. 
Antibody Specificity Category Clone Source Working dilution 
Keratin 3 (K3)* 
Differentiated 
corneal epithelial 
cells 
Mouse monoclonal AE5 Mp Biomedical (Illkirch, France) 1:50 
Keratin 15 (K15) 
Limbal epithelial 
stem cells Mouse monoclonal LHK15 
Millipore 
(Billerica, MA, USA) 1:50 
Alpha isoform of 
nuclear protein 63 
(p63alpha) 
Limbal epithelial 
stem cells Rabbit polyclonal - 
Cell Signaling 
(Danvers, MA, USA) 1:50 
*K3 and K12 are the most specific markers for the corneal epithelium, and they are not expressed in limbal epithelial stem cells. 
Either of these markers can be used to determine the corneal epithelial phenotype. 
 
Table S2. Characterization of cultivated limbal epithelial cells and bone marrow-derived 
mesenchymal stem cells for transplantation (CLET and MSCT, respectively). 
Sample 
Mean time ofculture on 
amniotic membrane 
Mean % of 
K3 
Mean % of 
K15 
Mean % of 
p63alpha Cell morphology Cell stratification 
CLET 3 – 4 weeks 80 90 70 Cuboidal  No 
MSCT 3 – 5 days 90 90 90 Elongated  No 
K: Keratin; p63alpha: Alpha isoform of nuclear protein 63. 
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Supplemental Figure 
Figure S1. Characterization of cultivated limbal epithelial cells and bone marrow-derived 
mesenchymal stem cells for transplantation (CLET and MSCT, respectively). Representative 
images captured by phase contrast (20X magnification) and immunofluorescence microscopes (40X 
magnification), n=4. Corneal epithelial cell (K3) and limbal epithelial stem cell (K15 and p63alpha) 
markers were analyzed. Green, K3, K15, and p63alpha marker expression; red, nuclei counterstained 
with propidium iodide. 
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Supplemental Discussion of Immunofluorescence Results 
The quality of the transplanted amniotic membrane-containing cell grafts (CLET or MSCT) were 
characterized in parallel. We observed that around 80% of limbal epithelial cells cultured on amniotic 
membranes expressed the limbal epithelial stem cell markers K15 and p63alpha. This was consistent 
with the results previously reported by Zakaria et al.,12 although the data are not directly comparable 
due to different culture media and scaffolds that were used by these authors. In their amniotic 
membrane-limbal epithelial cell grafts, the predominant phenotype (>50%) consisted of cells that 
expressed ABCG2, ΔNp63, and K14 markers. Moreover, these authors reported negative expression 
for the corneal proteins K3/12 and desmoglein.12 In contrast, we found that protein K3 was also 
expressed by about 80% of limbal cells on grafts, showing that at least some of these cells expressed 
limbal epithelial stem cell markers and corneal markers at the same time. These results could 
suggest the presence of a high percentage of transient amplifying cells (K15+, p63alpha+, and K3+) in 
amniotic membrane-limbal epithelial cell grafts. These data agree with the fact that human limbal 
epithelium contains mainly transient amplifying cells and that limbal epithelial stem cells represent 
less than 10% of the total limbal basal cell population.13–15 Therefore, our grafts would be suitable for 
ocular surface treatment. This is consistent with the finding of Rama et al.,16 who reported that 
cultures containing more than 3% p63 positive cells have a high probability of leading to successful 
corneal epithelial regeneration. In contrast, cultures with 3% or less p63 positive cells have a lower 
probability for successful corneal regeneration. Their data are not directly comparable to ours 
because of the different culture conditions. On the other hand, it is not possible to rule out the 
potential migration of limbal MSC from the limbal explant stroma to the amniotic membrane under 
culture conditions. In fact, this could be an explanation for the high expression of K3 and p63alpha 
observed in CLET cultures, as different authors have reported K3 and p63alpha expression in MSC 
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cultured on amniotic membrane.17–22 However, the morphology observed by both phase contrast and 
immunofluorescence microscopy in the LESC cultures was polygonal, more similar to epithelial-like 
cells, suggesting that it is very unlikely that MSC from limbal stroma were contaminating the CLET 
cultures. Mesenchymal stem cells cultivated on amniotic membranes were positive for K3 and K15 
proteins. These data agree with previous studies in which different cytokeratins (K3, K12, K18) were 
expressed by cells obtained from bone marrow or adipose tissues.17–21 In addition, we detected the 
p63alpha marker in cells cultivated on the amniotic membranes, in accordance with results reported 
by other investigators.22–24 However, the expression of this marker by mesenchymal stem cells is 
currently controversial because several groups showed that MSC did not express p63 protein.18,20 
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